52-Week Range
$720 – $960
Mid-range, correcting
Q1 2026 Revenue
$19.8B
+56% YoY
GLP-1 Revenue (Q1)
$12.8B
Mounj. $8.7B + Zepb. $4.1B
FY2026E Revenue Guide
$82–$85B
+32–37% YoY
P/E (FY2026E)
35.4×
$23.65E non-GAAP EPS
Analyst Consensus
Strong Buy
31B · 3H · 0S
12-Month Price History
Income Statement Forecast ($B) · E = Estimate
| FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|---|---|---|
| Key Product Revenue | |||||||
| Mounjaro (tirzepatide, T2D) | $0.5B | $5.2B | $11.5B | $19.8B | $30.0B | $38.0B | $44.0B |
| Zepbound (tirzepatide, obesity) | — | $0.2B | $4.9B | $10.4B | $17.0B | $22.0B | $26.0B |
| Combined GLP-1 | $0.5B | $5.4B | $16.4B | $30.2B | $47.0B | $60.0B | $70.0B |
| Verzenio (abemaciclib) | $1.4B | $2.1B | $3.0B | $3.6B | $3.9B | $4.1B | $4.1B |
| Jardiance + Other | $5.5B | $6.3B | $7.2B | $8.0B | $8.5B | $8.8B | $9.0B |
| Other / Pipeline | $21.3B | $21.3B | $16.4B | $20.3B | $24.6B | $28.0B | $32.0B |
| Total Revenue | $28.5B | $34.1B | $45.0B | $62.6B | $83.5B | $100.8B | $115.0B |
| YoY Growth | +1% | +20% | +32% | +39% | +33% | +21% | +14% |
| Profitability | |||||||
| Gross Margin | 72.3% | 72.9% | 77.1% | 80.1% | 81.5% | 82.5% | 83.0% |
| Non-GAAP Op. Margin | 30.0% | 31.6% | 34.0% | 36.5% | 38.5% | 41.0% | 43.0% |
| Non-GAAP EPS | $7.93 | $10.00 | $13.73 | $19.40 | $23.65 | $30.20 | $37.50 |
| EPS Growth YoY | +19% | +26% | +37% | +41% | +22% | +28% | +24% |
Balance Sheet & Cash Flow ($B)
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Cash & Short-Term Inv. | $3.0B | $3.4B | $4.8B | $6.0B | $9.5B | $15.0B |
| Total Debt | $19.9B | $26.2B | $28.5B | $27.0B | $23.0B | $18.0B |
| Manufacturing Capex (Committed) | $3.2B | $5.0B | $7.8B | $10.0B | $8.5B | $6.0B |
| Cash Flow | ||||||
| Operating Cash Flow | $6.2B | $8.6B | $14.5B | $22.0B | $30.0B | $38.0B |
| Capital Expenditures | -$3.2B | -$5.0B | -$7.8B | -$10.0B | -$8.5B | -$6.0B |
| Free Cash Flow | $3.0B | $3.6B | $6.7B | $12.0B | $21.5B | $32.0B |
| FCF Margin | 8.7% | 8.0% | 10.7% | 14.4% | 21.3% | 27.8% |
GLP-1 Revenue Ramp & EPS Growth
Total Revenue
GLP-1 Revenue
Estimated
Valuation Framework
Base Case Price Target
$1,050
44.4× FY2026E non-GAAP EPS · +25% upside
DCF (10yr, 9% WACC, 3% terminal)
$970–$1,150
Peak GLP-1 TAM of $150B+ by 2032; tirzepatide dominance
| Metric | LLY Current | LLY @ PT $1,050 | NVO (Peer) | VRTX (Peer) |
|---|---|---|---|---|
| Market Cap | ~$750B | ~$940B | ~$310B | ~$135B |
| P/E Non-GAAP (2026E) | 35.4× | 44.4× | ~28× | ~26× |
| Rev Growth (2026E) | +33% | — | -2% (NVO, Ozempic capped) | +13% |
| GLP-1 Mkt Share (2026E) | ~55% | — | ~43% | N/A |
| FCF Yield (2026E) | 1.6% | 1.3% | 2.8% | 3.5% |
| Consensus PT | $960 | — | $130 | $610 |
LLY's premium to NVO is justified by faster revenue growth (tirzepatide superiority over semaglutide in SURMOUNT-5), broader indication expansion (HFpEF, sleep apnea, NASH), and the oral GLP-1 pipeline that NVO has yet to match. The 35x forward PE compresses toward 25x as FCF inflects in 2027.
12-Month Price Target Scenarios
Bull Case
$1,300
+55% upside
Orforglipron oral GLP-1 Phase 3 success unlocks mass-market / price-sensitive segment. Retatrutide (triple agonist) shows superior weight loss >30%. Manufacturing resolves ahead of schedule; supply shortage era ends. Revenue reaches $95B in FY2026E. Multiple re-rates to 55x on duration extension.
Base Case
$1,050
+25% upside
GLP-1 revenue hits $47B in FY2026E. Manufacturing supply meets demand by Q4 2026. Heart failure + sleep apnea labels add meaningful new patient pools. FY2026 EPS of $23.65 tracking toward $30 in FY2027. Multiple holds at 44x on high-conviction growth.
Bear Case
$620
-26% downside
IRA Medicare price negotiation on Mounjaro cuts pricing 40%. Compounding pharmacies capture 25%+ of market. NVO launches superior next-gen obesity drug. Revenue growth decelerates to 15%; manufacturing overcapacity creates write-downs. Multiple compresses to 26x.
Key Catalysts — Next 12 Months
Jul 30, 2026
Q2 2026 Earnings — GLP-1 Volume Inflection
Q2 will confirm if Mounjaro/Zepbound supply constraints are easing. Street models Q2 combined GLP-1 at $14B+. A beat + supply update indicating Q4 full market access would be the single largest near-term catalyst. We model Q2 revenue of $22B and EPS of $5.80+.
H2 2026
Orforglipron Phase 3 Readout — Oral GLP-1
Orforglipron is a once-daily oral GLP-1 agonist in Phase 3 for both obesity and T2D. If it matches injectable efficacy (15%+ weight loss) at an accessible price point, it unlocks the 85% of obese patients who cannot or will not self-inject. Estimated $15B+ peak sales opportunity alone.
2026
HFpEF Label — Heart Failure Approval Ramp
Tirzepatide received FDA approval for heart failure with preserved ejection fraction (HFpEF) — affecting 6M US patients. This is the first effective therapy for HFpEF and creates a distinct formulary position beyond obesity/T2D. Cardiology prescribing dynamics differ meaningfully from endocrinology, opening a new distribution channel.
2026–2027
Retatrutide Phase 3 — Triple Agonist
Retatrutide (GIP/GLP-1/glucagon triple agonist) showed 24.2% weight loss at 48 weeks in Phase 2 — the highest weight loss of any drug in clinical trials. Phase 3 data in 2026-2027 could establish retatrutide as the successor to tirzepatide, extending LLY's GLP-1 leadership well beyond 2030.
Risk Register
High
IRA Medicare Price Negotiation
The Inflation Reduction Act authorizes Medicare to negotiate GLP-1 drug prices starting 2028–2030 as these drugs age into the eligibility window. With Mounjaro at ~$1,000/month list price, a negotiated price of $400–600 would materially reduce LLY's margin profile. The full impact would not be felt until FY2029–2030 but is a known long-term headwind.
High
Compounding Pharmacy & Biosimilar Competition
FDA-authorized compounding pharmacies have been dispensing semaglutide and tirzepatide at 70–80% discounts during the shortage period. As supply normalizes, FDA is expected to end the shortage designation and ban compounding — but legal battles are ongoing. Any delay in FDA enforcement extends the period of illicit competition.
Med
Manufacturing Scale-Up Execution
Lilly has committed $25B+ to manufacturing expansion across US (Indiana, NC), Germany, Ireland, and China. Delays in facility approvals, fill-finish capacity, or active pharmaceutical ingredient (API) yield would extend the supply constraint and throttle revenue growth below forecast.
Low
Next-Gen Competitor Pipeline
Novo Nordisk (CagriSema), Amgen (MariTide), and Roche (CT-388) are all in Phase 3 with next-gen obesity drugs. While SURMOUNT-5 confirmed tirzepatide superiority over semaglutide, a next-gen drug with >25% weight loss and once-monthly dosing could challenge LLY's market share beyond 2028.
Market Sentiment & Positioning
Analyst Rating
Strong Buy
31B · 3H · 0S
Avg Price Target
$960
Range: $800 – $1,200
Hedge Fund Flow
Positive
Top biotech holding HFs
Insider Activity
Neutral
Small programmatic sales
Short Interest
0.9%
Very low; strong conviction
SmartScore
9/10
Top Performer
The Bottom Line
▶ Investment Conclusion · BUY · PT $1,050
Eli Lilly is not just a pharmaceutical stock — it is a platform company in the largest therapeutic category in history. Obesity affects 1 billion people globally; GLP-1 drugs have proven they can treat not just weight but the downstream cardiovascular, metabolic, neurological, and oncological consequences of metabolic dysfunction. Tirzepatide's superiority across every head-to-head trial, combined with the broadest indication pipeline of any GLP-1, makes LLY the most durable growth story in large-cap pharma.
The manufacturing constraint that suppressed 2024–2025 revenue is resolving; FCF inflects sharply in 2027 as operating leverage compounds on the $83.5B revenue base. At 35x forward earnings, the market is still not fully pricing in the $100B revenue trajectory by FY2028. We rate LLY BUY with a PT of $1,050.
The manufacturing constraint that suppressed 2024–2025 revenue is resolving; FCF inflects sharply in 2027 as operating leverage compounds on the $83.5B revenue base. At 35x forward earnings, the market is still not fully pricing in the $100B revenue trajectory by FY2028. We rate LLY BUY with a PT of $1,050.
MARKET BUZZ RESEARCH — Informational purposes only. Not financial advice. Data as of May 31, 2026.